Drug-anaesthetic interaction in phMRI: the case of the psychotomimetic agent phencyclidine

Magnetic Resonance Imaging

Volumn 26, Issue 7, 2008, Pages 999-1006

  Gozzi, Alessandro ^a   Schwarz, Adam ^a   Crestan, Valerio ^a   Bifone, Angelo ^a  

^a GSK   (Italy)

Author keywords

Anaesthesia; Anesthesia; CBV; fMRI; Halothane; NMDA; PCP; Phencyclidine; phMRI; Rat; Schizophrenia

Indexed keywords

DEOXYGLUCOSE; HALOTHANE; PHENCYCLIDINE;

ANESTHESIA; ANIMAL EXPERIMENT; ARTICLE; BRAIN MAPPING; CONTROLLED STUDY; DOSE RESPONSE; MALE; NEUROIMAGING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RAT; SCHIZOPHRENIA; STATISTICAL SIGNIFICANCE;

ANESTHETICS, INHALATION; ANIMALS; BRAIN; BRAIN MAPPING; DRUG INTERACTIONS; HALLUCINOGENS; HALOTHANE; IMAGE PROCESSING, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MALE; PHENCYCLIDINE; RATS; RATS, SPRAGUE-DAWLEY;

ANIMALIA; RATTUS;

EID: 48549090047     PISSN: 0730725X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mri.2008.01.012     Document Type: Article

References (46)

1. Wise R.G., and Tracey I. The role of fMRI in drug discovery. J Magn Reson Imaging 23 6 (2006) 862-876
2. Schwarz A.J., Zocchi A., Reese T., Gozzi A., Garzotti M., Varnier G., et al. Concurrent pharmacological MRI and in situ microdialysis of cocaine reveal a complex relationship between the central hemodynamic response and local dopamine concentration. NeuroImage 23 1 (2004) 296-304
3. Gozzi A., Schwarz A.J., Reese T., Bertani S., Crestan V., and Bifone A. Region-specific effects of nicotine on brain activity: a pharmacological MRI study in the drug-naïve rat. Neuropsychopharmacology 31 8 (2005) 1690-1703
4. Schwarz A.J., Gozzi A., Reese T., and Bifone A. In vivo mapping of functional connectivity in neurotransmitter systems using pharmacological MRI. NeuroImage 34 4 (2007) 1627-1636
5. Kalisch R., Salome N., Platzer S., Wigger A., Czisch M., Sommer W., et al. High trait anxiety and hyporeactivity to stress of the dorsomedial prefrontal cortex: a combined phMRI and Fos study in rats. NeuroImage 23 1 (2004) 382-391
6. Gozzi A., Ceolin L., Schwarz A.J., Reese T., Bertani S., and Bifone A. A multimodality investigation of cerebral haemodynamics and autoregulation in phMRI. Magnetic Resonance Imaging 25 6 (2007) 826-833
7. Steward C.A., Marsden C.A., Prior M.J., Morris P.G., and Shah Y.B. Methodological considerations in rat brain BOLD contrast pharmacological MRI. Psychopharmacology (Berl) 180 4 (2005) 687-704
8. Grasshoff C., Drexler B., Rudolph U., and Antkowiak B. Anaesthetic drugs: linking molecular actions to clinical effects. Curr Pharm Des 12 28 (2006) 3665-3679
9. Domino E.F. Neurobiology of phencyclidine (Sernyl), a drug with an unusual spectrum of pharmacological activity. Int Rev Neurobiol 6 (1964) 303-347
10. Adler C.M., Malhotra A.K., Elman I., Goldberg T., Egan M., Pickar D., et al. Comparison of ketamine-induced thought disorder in healthy volunteers and thought disorder in schizophrenia. Am J Psychiatry 156 10 (1999) 1646-1649
11. Lahti A.C., Weiler M.A., Tamara Michaelidis B.A., Parwani A., and Tamminga C.A. Effects of ketamine in normal and schizophrenic volunteers. Neuropsychopharmacology 25 4 (2001) 455-467
12. Morris B.J., Cochran S.M., and Pratt J.A. PCP: from pharmacology to modelling schizophrenia. Curr Opin Pharmacol 5 1 (2005) 101-106
13. Heresco-Levy U., Javitt D.C., Ermilov M., Mordel C., Silipo G., and Lichtenstein M. Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia. Arch Gen Psychiatry 56 1 (1999) 29-36
14. Goff D.C., Leahy L., Berman I., Posever T., Herz L., Leon A.C., et al. A placebo-controlled pilot study of the ampakine CX516 added to clozapine in schizophrenia. J Clin Psychopharmacol 21 5 (2001) 484-487
15. Krystal J.H., Anand A., and Moghaddam B. Effects of NMDA receptor antagonists: implications for the pathophysiology of schizophrenia. Arch Gen Psychiatry 59 7 (2002) 663-664
16. Langsjo J.W., Kaisti K.K., Aalto S., Hinkka S., Aantaa R., Oikonen V., et al. Effects of subanesthetic doses of ketamine on regional cerebral blood flow, oxygen consumption, and blood volume in humans. Anesthesiology 99 3 (2003) 614-623
17. Deakin J.F.W., Lees J., McKie S., Hallak J.E.C., Williams S.R., and Dursun S.M. Glutamate and the neural basis of the subjective effects of ketamine: a pharmaco-magnetic resonance imaging study. Arch Gen Psychiatry 65 2 (2008) 154-164
18. Gozzi A., Large C.H., Schwarz A., Bertani S., Crestan V., and Bifone A. Differential effects of antipsychotic and glutamatergic agents on the phMRI response to phencyclidine. Neuropsychopharmacology (2007) [in press]
19. Littlewood C.L., Jones N., O'Neil M.J., Mitchell S.N., Tricklebank M., and Williams M.S. Mapping the central effects of ketamine in the rat using pharmacological MRI. Psychopharmacology 186 1 (2006) 64-81
20. Schwarz A., Gozzi A., Reese T., Bertani S., Crestan V., Hagan J., et al. Selective dopamine D(3) receptor antagonist SB-277011-A potentiates phMRI response to acute amphetamine challenge in the rat brain. Synapse 54 1 (2004) 1-10
21. Chen Y.C., Galpern W.R., Brownell A.L., Matthews R.T., Bogdanov M., Isacson O., et al. Detection of dopaminergic neurotransmitter activity using pharmacologic MRI: correlation with PET, microdialysis, and behavioral data. Magn Reson Med 38 3 (1997) 389-398
22. Dixon A.L., Prior M., Morris P.M., Shah Y.B., Joseph M.H., and Young A.M. Dopamine antagonist modulation of amphetamine response as detected using pharmacological MRI. Neuropharmacology 48 2 (2005) 236-245
23. Chen Y.I., Choi J.K., and Jenkins B.G. Mapping interactions between dopamine and adenosine A2a receptors using pharmacologic MRI. Synapse 55 2 (2005) 80-88
24. Mandeville J.B., Marota J.J.A., Kosofsky B.E., Keltner J.R., Weissleder R., Rosen B., et al. Dynamic functional imaging of relative cerebral blood volume during rat forepaw stimulation. Magn Reson Med 39 (1998) 615-624
25. Weissman A.D., Dam M., and London E.D. Alterations in local cerebral glucose utilization induced by phencyclidine. Brain Res 435 1-2 (1987) 29-40
26. Schwarz A.J., Reese T., Gozzi A., and Bifone A. Functional MRI using intravascular contrast agents: detrending of the relative cerebrovascular (rCBV) time course. Magn Reson Imaging 21 10 (2003) 1191-1200
27. Schwarz A.J., Danckaert A., Reese T., Gozzi A., Paxinos G., Watson C., et al. A stereotaxic MRI template set for the rat brain with tissue class distribution maps and co-registered anatomical atlas: application to pharmacological MRI. NeuroImage 32 2 (2006) 538-550
28. Schwarz A.J., Whitcher B., Gozzi A., Reese T., and Bifone A. Study-level wavelet cluster analysis and data-driven signal models in pharmacological MRI. J Neurosci Methods 159 2 (2006) 346-360
29. Whitcher B., Schwarz A.J., Barjat H., Smart S.C., Grundy R.I., and James M.F. Wavelet-based cluster analysis: data-driven grouping of voxel time courses with application to perfusion-weighted and pharmacological MRI of the rat brain. NeuroImage 24 2 (2005) 281-295
30. Friston K.J., Jezzard P., and Turner R. Analysis of functional MRI time-series. Human Brain Mapping 1 2 (1994) 153-171
31. Worsley K.J., Evans A.C., Marrett S., and Neelin P. A three-dimensional statistical analysis for CBF activation studies in human brain. J Cereb Blood Flow Metab 12 6 (1992) 900-918
32. Zaharchuk G., Mandeville J.B., Bogdanov Jr. A.A., Weissleder R., Rosen B.R., and Marota J.J. Cerebrovascular dynamics of autoregulation and hypoperfusion. An MRI study of CBF and changes in total and microvascular cerebral blood volume during hemorrhagic hypotension. Stroke 30 10 (1999) 2197-2204
33. Choi J.K., Chen Y.I., Hamel E., and Jenkins B.G. Brain hemodynamic changes mediated by dopamine receptors: role of the cerebral microvasculature in dopamine-mediated neurovascular coupling. NeuroImage 30 3 (2006) 700-712
34. Schwarz A.J., Gozzi A., Reese T., Heidbreder C.A., and Bifone A. Pharmacological modulation of functional connectivity: the correlation structure underlying the phMRI response to d-amphetamine modified by selective dopamine D3 receptor antagonist SB277011A. Magn Reson Imag 25 6 (2007) 811-820
35. Preece M.A., Sibson N.R., Raley J.M., Blamire A., Styles P., and Sharp T. Region-specific effects of a tyrosine-free amino acid mixture on amphetamine-induced changes in BOLD fMRI signal in the rat brain. Synapse 61 11 (2007) 925-932
36. Duncan G.E., Moy S.S., Knapp D.J., Mueller R.A., and Breese G.R. Metabolic mapping of the rat brain after subanesthetic doses of ketamine: potential relevance to schizophrenia. Brain Res 787 2 (1998) 181-190
37. Duncan G.E., Leipzig J.N., Mailman R.B., and Lieberman J.A. Differential effects of clozapine and haloperidol on ketamine-induced brain metabolic activation. Brain Res 812 1-2 (1998) 65-75
38. Duncan G.E., Miyamoto S., Leipzig J.N., and Lieberman J.A. Comparison of brain metabolic activity patterns induced by ketamine, MK-801 and amphetamine in rats: support for NMDA receptor involvement in responses to subanesthetic dose of ketamine. Brain Res 843 1-2 (1999) 171-183
39. Duncan G.E., Miyamoto S., Leipzig J.N., and Lieberman J.A. Comparison of the effects of clozapine, risperidone, and olanzapine on ketamine-induced alterations in regional brain metabolism. J Pharmacol Exp Ther 293 1 (2000) 8-14
40. Miyamoto S., Leipzig J.N., Lieberman J.A., and Duncan G.E. Effects of ketamine, MK-801, and amphetamine on regional brain 2-deoxyglucose uptake in freely moving mice. Neuropsychopharmacology 22 4 (2000) 400-412
41. Homayoun H., Jackson M.E., and Moghaddam B. Activation of metabotropic glutamate 2/3 receptors reverses the effects of NMDA receptor hypofunction on prefrontal cortex unit activity in awake rats. J Neurophysiol 93 4 (2005) 1989-2001
42. Cavazzuti M., Porro C.A., Biral G.P., Benassi C., and Barbieri G.C. Ketamine effects on local cerebral blood flow and metabolism in the rat. J Cereb Blood Flow Metab 7 6 (1987) 806-811
43. Farber N.B. The NMDA receptor hypofunction model of psychosis. Ann N Y Acad Sci 1003 (2003) 119-130
44. Greene R. Circuit analysis of NMDAR hypofunction in the hippocampus, in vitro, and psychosis of schizophrenia. Hippocampus 11 5 (2001) 569-577
45. Mody I., Tanelian D.L., and MacIver M.B. Halothane enhances tonic neuronal inhibition by elevating intracellular calcium. Brain Res 538 2 (1991) 319-323
46. Risterucci C., Jeanneau K., Schoppenthau S., Bielser T., Kunnecke B., von Kienlin M., et al. Functional magnetic resonance imaging reveals similar brain activity changes in two different animal models of schizophrenia. Psychopharmacology (Berl) 180 4 (2005) 724-734